Conclusion of a non-exclusive discount agreement pursuant to Section 130a Paragraph 8 SGB V for the active ingredient progesterone exclusively in the dosage form VKA, (OBO) ATC G03DA04 for the period 01.03.2025 - 28.02.2027 - 32514

World Biggest Tenders Source

This tender with title Conclusion of a non-exclusive discount agreement pursuant to Section 130a Paragraph 8 SGB V for the active ingredient progesterone exclusively in the dosage form VKA, (OBO) ATC G03DA04 for the period 01.03.2025 - 28.02.2027 - 32514 has been published on Bidding Source portal dated 24 Jan 2025 for the country of Germany. It has been categorized on Pharmaceutical products. For similar tenders you can see tenders mentioned below of this page.

General Information

Germany

Tender Title :

Conclusion of a non-exclusive discount agreement pursuant to Section 130a Paragraph 8 SGB V for the active ingredient progesterone exclusively in the dosage form VKA, (OBO) ATC G03DA04 for the period 01.03.2025 - 28.02.2027 - 32514

Tender Type :

Invitation for Bids

Country :

Germany

Publish Date :

24 Jan 2025

Closing Date :

5 Jan 2027

Notice Language :

English

Tender Categories (CPVs) :

Pharmaceutical products

Full Tender Details :

For viewing full details of tenders, you should Log in to your account. If not registered yet, Please Register Now

Or Request a call back now and one of our representatives will contact you. Contact us

Similar Tenders

Conclusion of a non-exclusive drug discount agreement pursuant to Section 130a Paragraph 8 of the Social Code Book V by means of an open-house model for the active ingredient aripiprazole for parenteral administration (ATC code according to WHO: N05AX12) - 48010 Germany Conclusion of a non-exclusive drug discount agreement pursuant to Section 130a Paragraph 8 of the Social Code Book V by means of an open-house model for the active ingredient Natalizumab (ATC code according to WHO: L04AG03) - 47685 Germany Conclusion of non-exclusive discount agreements pursuant to Section 130 a Paragraph 8 SGB V in the period from 01.03.2025 to 31.12.2026 - 47306 Germany Conclusion of a non-exclusive drug discount agreement pursuant to Section 130a Paragraph 8 of the Social Code Book V by means of an open-house model for the active ingredient Rivaroxaban (ATC code according to WHO: B01AF01) - 49081 Germany Open House Original Discount Contracts 2025-01 - Bictegravir/Emtricitabine/Tenofovir alafenamide (Biktarvy(R)) - 39458 Germany Pharmaceutical discount agreements pursuant to Section 130a Paragraph 8 of the Social Security Code (SGB V) within the framework of open-house procedures - 35521 Germany Pharmaceutical discount agreements pursuant to Section 130a Paragraph 8 of the Social Security Code (SGB V) within the framework of open-house procedures - 31281 Germany Open house drug discount contracts Colecalciferol, non RX, exclusively according to Annex 1 AM-RL G-BA prescribable products, ATC A11CC05 - 33054 Germany Open house drug discount agreements Goserelin, ATC L02AE03 - 34866 Germany Open house drug discount agreements Botulinum toxin type A, finished medicinal product name Xeomin(R), ATC M03AX21 - 34179 Germany

Conclusion of a non-exclusive discount agreement pursuant to Section 130a Paragraph 8 SGB V for the active ingredient progesterone exclusively in the dosage form VKA, (OBO) ATC G03DA04 for the period 01.03.2025 - 28.02.2027 - 32514

General Information

Germany

Similar Tenders

Pharmaceutical products Tenders

Germany Tenders

Europe Tenders

Tenders

info@biddingsource.com